Just caught Bristol Myers Squibb's February run and honestly, the stock move makes sense when you look at what's actually happening under the hood.

So the company dropped its full-year 2025 earnings report early in the month, and while the headline numbers look a bit rough on the surface—revenue only inched up 1% to $12.5B, and non-GAAP net income took a 24% hit—there's a much more interesting story here. The market clearly saw it, which is why BMY popped over 13% during the month.

Here's the thing: Bristol Myers is basically in transition. Their legacy drug portfolio (think Eliquis, the blood thinner they share profits on with Pfizer) is getting hammered—revenue down 15% to just over $5.1B. That's the painful part everyone focuses on. But meanwhile, their growth portfolio is absolutely firing on all cylinders. Opdivo and the newer cancer drugs grew 16% to nearly $7.4B. That's where the real story is.

The company also beat analyst expectations pretty clearly. Wall Street was looking for around $12.2B in revenue and $1.12 per share in adjusted net income. Bristol Myers delivered better than that.

What really got investors excited though was the forward guidance. Management is projecting $46-47.5B in revenue for 2026 with adjusted net income of $6.05 to $6.35 per share. Even at the low end, that beats what analysts were expecting ($44B+ and $6.02 per share). Yeah, there's a slight revenue dip expected compared to 2025's $48.2B, but that's expected given the Eliquis price cuts to Medicare and retail patients. Not really a concern when you factor that in.

The pipeline progress was another bright spot. Mid-February, the FDA accepted their new drug application for iberdomide in multiple myeloma combination therapy. They also released positive Phase 2 data on Reblozyl for specialized anemia treatment. That's the kind of news that shows the company has real runway ahead.

Look, the legacy portfolio is still going to be a drag for a while—that's just the nature of the pharma business. But the growth side is solid, and the pipeline looks promising. This feels like one of those stocks that rewards patience. The February move was justified, and if you're looking at healthcare names with actual growth catalysts, this one's worth watching.